Please provide your email address to receive an email when new articles are posted on . BARCELONA, Spain — In this Healio Video Perspective from the Euretina congress, Paulo-Eduardo Stanga, MD, ...

Please provide your email address to receive an email when new articles are posted on . The trial, which included 27 participants, met its safety and efficacy endpoints at 52 weeks and 76 weeks. The ...

A blind man has had his vision partially restored using optogenetic therapy and engineered goggles -- the first successful case of such therapy in humans. Researchers treated a 58-year-old man who for ...

DALLAS, Dec. 2, 2025 /PRNewswire/ -- Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor ...

As a child, Max Hodak learned to develop film in a darkroom with his grandfather who was almost blind. Hodak's grandfather had retinitis pigmentosa, a congenital disease that affects one out of every ...

GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal ...

- Company will advance RTx-021 for the treatment of geographic atrophy age-related macular degeneration SAN FRANCISCO--(BUSINESS WIRE)--Ray Therapeutics, a leading optogenetics company, announced ...

One of the hallmarks of cancer cells is their ability to evade apoptosis, or programmed cell death, through changes in protein expression. Inducing apoptosis in cancer cells has become a major focus ...